Sharkey John W. 4

What Happened

• John W. Sharkey, Vice President of Business Development at GeoVax Labs, was granted a derivative award on 2026-06-17: 17,600 shares listed at $0.00 (a stock option/award reported as an acquisition). No cash was paid on grant; the filing shows a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-17; Filing date (Form 4): 2026-06-22 (filed late relative to the 2-business-day reporting window).
• Award details: 17,600 shares reported at $0.00 (derivative instrument). Footnote F1: the stock option becomes exercisable in three equal annual installments on the first three anniversaries of the grant.
• Shares owned after the transaction: not specified in the provided summary — check the full Form 4 for total holdings and strike price/exercise terms.
• No sale or immediate cash exercise reported; this is a grant of options/awards (transaction code A).

Context

• This is a standard equity compensation grant (an option award) that vests over time; it does not reflect an immediate purchase or sale. For investors, grants are routine for executives and may simply reflect compensation rather than a signal of buying or selling intent. The late filing reduces the timeliness of disclosure.